Wednesday, July 8, 2026

pharma · Non-small Cell Lung Cancer · Epilepsy

Eisai

Eisai clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Tokyo, Japan, JP HQ
41 Employees
NMPA registrant Type
Company details
Intelligence · Clinical Programs

Eisai projects

4 ClinicalTrials.gov programs sponsored by Eisai.

Eisai has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. E0302 SR1

    Eisai Co.,

    Healthy Subjects

    phase 1 small molecule completed

    1 trial
  2. E6007

    Eisai Co.,

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  3. E7080

    Eisai Co.,

    Cancer: Solid Tumors

    phase 1 small molecule completed

    1 trial
  4. E7766

    Eisai Co.,

    Lymphoma

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Eisai have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.